AMIKACIN KABI amikacin (as sulfate) 1000 mg/200 mL solution for injection bottle Australia - English - Department of Health (Therapeutic Goods Administration)

amikacin kabi amikacin (as sulfate) 1000 mg/200 ml solution for injection bottle

fresenius kabi australia pty ltd - amikacin sulfate, quantity: 1336 mg (equivalent: amikacin, qty 1000 mg) - solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections; hydrochloric acid - amikacin kabi is indicated in the short-term treatment of serious infections caused by susceptible strains of gram-negative bacteria, (see section 5.1 pharmacodynamic properties). staphylococcus aureus, including methicillin-resistant strains is the principal gram-positive organism sensitive to amikacin. the use of amikacin in the treatment of staphylococcal infections should be restricted to second-line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of stapylococcus who have failed to respond or are allergic to other available antibiotics. amikacin kabi is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used. in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to gram-positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in-vitro mixing of the two drugs causes inactivation of amikacin. clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra-abdominal organs, post-operative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

AMIKACIN KABI amikacin (as sulfate) 250 mg/50 mL solution for injection bottle Australia - English - Department of Health (Therapeutic Goods Administration)

amikacin kabi amikacin (as sulfate) 250 mg/50 ml solution for injection bottle

fresenius kabi australia pty ltd - amikacin sulfate, quantity: 334 mg (equivalent: amikacin, qty 250 mg) - solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections; hydrochloric acid - amikacin kabi is indicated in the short-term treatment of serious infections caused by susceptible strains of gram-negative bacteria, (see section 5.1 pharmacodynamic properties). staphylococcus aureus, including methicillin-resistant strains is the principal gram-positive organism sensitive to amikacin. the use of amikacin in the treatment of staphylococcal infections should be restricted to second-line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of stapylococcus who have failed to respond or are allergic to other available antibiotics. amikacin kabi is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used. in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to gram-positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in-vitro mixing of the two drugs causes inactivation of amikacin. clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra-abdominal organs, post-operative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

AMIKACIN KABI amikacin (as sulfate) 500 mg/100 mL solution for injection bottle Australia - English - Department of Health (Therapeutic Goods Administration)

amikacin kabi amikacin (as sulfate) 500 mg/100 ml solution for injection bottle

fresenius kabi australia pty ltd - amikacin sulfate, quantity: 668 mg (equivalent: amikacin, qty 500 mg) - solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections; hydrochloric acid - amikacin kabi is indicated in the short-term treatment of serious infections caused by susceptible strains of gram-negative bacteria, (see section 5.1 pharmacodynamic properties). staphylococcus aureus, including methicillin-resistant strains is the principal gram-positive organism sensitive to amikacin. the use of amikacin in the treatment of staphylococcal infections should be restricted to second-line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of stapylococcus who have failed to respond or are allergic to other available antibiotics. amikacin kabi is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used. in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to gram-positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in-vitro mixing of the two drugs causes inactivation of amikacin. clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra-abdominal organs, post-operative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

AMIKACIN MEDICIANZ amikacin (as sulfate) 500 mg/2 mL solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

amikacin medicianz amikacin (as sulfate) 500 mg/2 ml solution for injection vial

medsurge pharma pty ltd - amikacin sulfate, quantity: 667.6 mg (equivalent: amikacin, qty 500 mg) - injection, solution - excipient ingredients: water for injections; sodium metabisulfite; sodium citrate dihydrate; sulfuric acid - amikacin injection is indicated in the short-term treatment of serious infections caused by susceptible strains of gram-negative bacteria, (see section 5.1 pharmacodynamic properties).,staphylococcus aureus, including methicillin-resistant strains is the principal gram-positive organism sensitive to amikacin.,the use of amikacin in the treatment of staphylococcal infections should be restricted to second-line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of staphylococcus who have failed to respond or are allergic to other available antibiotics.,amikacin injection is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.,in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to gram-positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in-vitro mixing of the two drugs causes inactivation of amikacin.,clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra- abdominal organs, post-operative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

AMIKACIN MEDSURGE amikacin (as sulfate) 500 mg/2 mL solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

amikacin medsurge amikacin (as sulfate) 500 mg/2 ml solution for injection vial

medsurge pharma pty ltd - amikacin sulfate, quantity: 667.6 mg (equivalent: amikacin, qty 500 mg) - injection, solution - excipient ingredients: sulfuric acid; sodium citrate dihydrate; sodium metabisulfite; water for injections - amikacin injection is indicated in the short-term treatment of serious infections caused by susceptible strains of gram-negative bacteria, (see section 5.1 pharmacodynamic properties).,staphylococcus aureus, including methicillin-resistant strains is the principal gram-positive organism sensitive to amikacin.,the use of amikacin in the treatment of staphylococcal infections should be restricted to second-line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of staphylococcus who have failed to respond or are allergic to other available antibiotics.,amikacin injection is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.,in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to gram-positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in-vitro mixing of the two drugs causes inactivation of amikacin.,clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra- abdominal organs, post-operative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

Amikacin Caragen 250 mg/ml solution for injection/infusion Ireland - English - HPRA (Health Products Regulatory Authority)

amikacin caragen 250 mg/ml solution for injection/infusion

caragen limited - amikacin - solution for injection/infusion - 250 milligram(s)/millilitre - amikacin

Amikacine B. Braun 2,5 mg/ml inf. sol. i.v. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amikacine b. braun 2,5 mg/ml inf. sol. i.v.

b. braun melsungen ag - amikacin sulfate 3,34 mg/ml - eq. amikacin 2,5 mg/ml - solution for infusion - 2,5 mg/ml - amikacin sulfate 3.34 mg/ml - amikacin

Amikacine B. Braun 5 mg/ml inf. sol. i.v. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amikacine b. braun 5 mg/ml inf. sol. i.v.

b. braun melsungen ag - amikacin sulfate 6,68 mg/ml - eq. amikacin 5 mg/ml - solution for infusion - 5 mg/ml - amikacin sulfate 6.68 mg/ml - amikacin

Amikacine B. Braun 10 mg/ml inf. sol. i.v. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amikacine b. braun 10 mg/ml inf. sol. i.v.

b. braun melsungen ag - amikacin sulfate 13,35 mg/ml - eq. amikacin 10 mg/ml - solution for infusion - 10 mg/ml - amikacin sulfate 13.35 mg/ml - amikacin

Amikacine Fresenius Kabi 5 mg/ml inf. sol. i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amikacine fresenius kabi 5 mg/ml inf. sol. i.v. vial

fresenius kabi sa-nv - amikacin sulfate 6,68 mg/ml - eq. amikacin 5 mg/ml - solution for infusion - 5 mg/ml - amikacin sulfate 6.68 mg/ml - amikacin